Business Context and Reporting Period
Silence Therapeutics Plc filed Form 6-K on June 27, 2024, to disclose positive initial results from the SANRECO Phase 1 repeat dose clinical trial of divesiran (SLN124). The filing incorporates a press release and investor presentation regarding the treatment of polycythemia vera (PV).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain a financial statement or quarterly results.
Material Changes and Clinical Results
The primary material update concerns the SANRECO Phase 1/2 clinical trial for divesiran, a siRNA targeting TMPRSS6. Key findings based on a data cut-off of March 29, 2024, include:
- Enrollment: 19 patients enrolled as of June 27, 2024, with 16 patients analyzed in the initial data set. Enrollment is expected to complete later in June 2024.
- Safety: Divesiran was observed to be well tolerated with no major safety issues reported.
- Efficacy (Phlebotomy Reduction):
- None of the 8 well-controlled patients (HCT ≤45%) required a phlebotomy during the treatment period.
- Of the 8 patients with HCT >45% at baseline, only 2 required a single phlebotomy; the remaining 6 required none.
- Notably, none of the 13 patients with baseline HCT levels of 50% or below required a phlebotomy to date.
- Biomarkers: Sustained reduction in hematocrit was observed across all dose groups. Hepcidin levels increased and were sustained within physiological levels, demonstrating target engagement.
Guidance, Outlook, and Risks
Outlook: The Company plans to complete enrollment in the SANRECO trial later in June 2024. Full results are expected to be presented at a future scientific meeting later in the year. The Company intends to advance divesiran into Phase 2 based on these results.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include the preliminary nature of the data, potential failure of later clinical trials, macroeconomic conditions (including conflicts in Ukraine and the Middle East), enrollment rates, regulatory uncertainties, and competition. The Company disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the full enrollment status of the SANRECO trial once the June 2024 completion date passes.
- Monitor the timing and content of the full data presentation at the upcoming scientific meeting.
- Review the Company's most recent Form 20-F (filed March 13, 2024) for detailed financial position and cash runway, as this 6-K contains no financial metrics.
- Assess the long-term sustainability of hepcidin levels and hematocrit control beyond the initial 34-week observation window.